Answers are grounded in this paper and cite their sources.
Hypertensive action was observed in conscious rats injected intraventricularly with glandular kallikrein (EC 3.4.21.35) in a dose-dependent manner (4-16 KU), which was associated with the enhancement of brain kinin level. Concurrently administered aprotinin, a kallikrein inhibitor, led to an inhibition of these effects of kallikrein. These results suggest that the central hypertensive action of kallikrein is mediated via the kinin liberated from a kininogen in the brain.
No takes yet. Share an insight, caveat, or question.
Kariya et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: